Why menopause and perimenopause change your weight and shape
The menopause transition changes body composition, not just the number on the scale. As estrogen (estradiol) declines, the body tends to store less fat in the hips and thighs and more in the abdomen as deeper visceral fat, the shift many women notice as new belly fat even when their weight is fairly stable (Climacteric / International Menopause Society, 2012).
Estrogen also helps maintain muscle, because estrogen receptors are present in muscle tissue and support muscle protein synthesis. Lower estrogen accelerates loss of lean muscle mass, and because muscle burns more energy at rest than fat, less muscle means a lower resting metabolic rate. Declining estrogen is also linked to reduced insulin sensitivity.
Total weight gain at midlife is multifactorial, however. Chronological aging, reduced activity and sleep changes all contribute, so menopause is more clearly tied to fat redistribution and muscle loss than to weight gain by itself (Climacteric / International Menopause Society, 2012).
- Fat shifts from hips and thighs toward the abdomen (visceral fat)
- Muscle (lean mass) declines, lowering resting metabolism
- Insulin sensitivity tends to fall
- Aging and lifestyle, not menopause alone, drive overall weight gain
Do GLP-1 medications work after menopause?
GLP-1 and dual GIP/GLP-1 medications are among the most effective weight-management drugs studied. In the STEP 1 trial, semaglutide 2.4 mg (Wegovy) produced a mean 14.9% body-weight loss over 68 weeks versus 2.4% on placebo (NEJM, 2021), and in SURMOUNT-1, tirzepatide (Zepbound) produced up to about 21% loss over 72 weeks (NEJM, 2022).
These landmark trials enrolled mostly women but at a mean age of roughly 45, so they were not designed around menopause. The best menopause-relevant evidence comes from a 2025 post hoc analysis of the SURMOUNT program (2,542 women), which found tirzepatide reduced body weight by about 23% in postmenopausal women versus about 3% on placebo, similar to perimenopausal women and close to premenopausal women (Obesity, 2025).
The takeaway: the available data suggest GLP-1 medications help postmenopausal women lose weight, but menopause-specific randomized trials are still limited, so the results should be read as promising rather than definitive. How these drugs work, by slowing gastric emptying and reducing appetite signals, does not appear to depend on menopause status.
- STEP 1: ~14.9% with semaglutide (NEJM, 2021)
- SURMOUNT-1: up to ~21% with tirzepatide (NEJM, 2022)
- Postmenopausal women: ~23% with tirzepatide in a 2025 SURMOUNT reanalysis (Obesity, 2025)
GLP-1 medications and hormone therapy (HRT)
There is no well-established harmful interaction between GLP-1 medications and menopause hormone therapy (HRT). In fact, two retrospective studies found that women using HRT lost somewhat more weight on a GLP-1: 16% versus 12% with semaglutide over 12 months in one analysis (Menopause, 2024), and a median 17% versus 14% with tirzepatide over about 18 months in a Mayo Clinic cohort (Endocrine Society / ENDO, 2025).
These are observational findings, not proof that HRT boosts GLP-1 results. Women who choose HRT may differ in other ways, and randomized trials are still underway. HRT is prescribed for menopausal symptoms and specific indications, not as a weight-loss drug, and whether it is right for you is a separate clinical decision.
One documented drug interaction is worth knowing, but it applies to oral birth control rather than menopause HRT: tirzepatide can reduce absorption of oral contraceptives, so the FDA label advises using a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. This is relevant for perimenopausal women who can still become pregnant (Lilly Medical, 2024).
Protecting muscle when weight comes off fast
Any rapid weight loss, from dieting or from a GLP-1, removes some muscle along with fat, and a meaningful share of the weight lost can be lean mass. That matters more at midlife, because menopause already accelerates muscle loss, and preserving muscle protects strength, metabolism and everyday function.
The evidence-based way to protect muscle during weight loss is resistance (strength) training plus adequate protein. In studies of older adults, resistance training during calorie restriction preserved most of the lean mass that would otherwise be lost, and commonly cited protein targets during active weight loss are around 1.2 to 1.6 g per kilogram of body weight per day. Discuss the right target for you with your clinician, especially if you have kidney disease.
- Do resistance or strength training at least 2 to 3 times per week
- Prioritize protein at each meal (about 1.2 to 1.6 g/kg/day for many adults)
- Lose weight gradually rather than crash-dieting on top of the medication
Bone density is a real midlife consideration
Postmenopausal women already lose bone faster because of estrogen decline, and weight loss itself can lower bone mineral density. Research indicates roughly a 1 to 2% drop in bone density per 10% of body weight lost, and larger losses after age 50 have been linked to higher hip-fracture risk (Journal of Bone and Mineral Research, 2016).
This does not mean avoiding needed weight loss, which carries its own major health benefits; it means being deliberate. Weight-bearing and resistance exercise, adequate protein, calcium and vitamin D, and where appropriate a bone-density (DXA) scan can all help protect the skeleton. Ask your clinician whether your bone health should be checked before or during treatment.
A tool used with lifestyle, and a clinician decides
GLP-1 medications are a tool, not a standalone fix. They work best alongside the same foundations that protect midlife health: enough protein, strength training, sleep, and managing other menopause symptoms. Brand GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) are FDA-approved; compounded semaglutide or tirzepatide is not FDA-approved and is not an equivalent product.
This page is educational and is not medical advice. Whether a GLP-1 is appropriate, and which one, at what dose, alongside HRT or not, depends on your full medical history and is a decision for you and a licensed clinician. GLP-1 medications carry warnings (including a boxed warning about thyroid C-cell tumors seen in rodents) and side effects, so a prescriber should weigh the benefits and risks for you.